Reimbursement and coverage risk
Pump adoption depends on third-party payor coverage and benefit design, especially in the U.S.
- Scope
- Medical and pharmacy benefit channels
- Materiality
- high
Tandem Diabetes Care, Inc
Tandem Diabetes Care designs and commercializes insulin delivery systems and diabetes technology for people who require intensive insulin therapy. Its portfolio includes insulin pumps, mobile applications, and related software and supplies sold in the United States and in international markets through a mix of direct operations and distributors.
−16,7 %
53,8 %
−20,2 %
+7,9 %
2.55
2.02
| % | |
|---|---|
| Insulin pumps | 45% Reusable insulin pump hardware used for intensive insulin therapy. |
| Consumables and supplies | 40% Cartridges, infusion sets, and other recurring pump-related supplies. |
| Automated insulin delivery software | 10% Algorithms and software features such as Control-IQ+ that automate dosing. |
| Digital diabetes applications and insights | 5% Connected software tools that support monitoring, training, and data review. |
Tandem sells primarily to people living with insulin-dependent diabetes, especially individuals with type 1 diabetes...
- Type 1 diabetes patientsprimary
Primary users of Tandem pumps and AID systems; they buy for intensive insulin management and convenience.
- Type 2 diabetes patients requiring intensive insulin therapysecondary
Adults eligible for pump therapy in selected markets; they buy for tighter glucose control and simpler dosing.
- Healthcare providers and diabetes clinicsprimary
Prescribe devices, support onboarding, and influence product selection based on clinical outcomes.
- Third-party payors and reimbursement systemsprimary
Influence access through medical and pharmacy benefit coverage and reimbursement terms.
Tandem is headquartered in the United States and sells in more than 25 countries worldwide. The U.S...
- •United States is the core market and main commercial base
- •Canada is served alongside the U.S. through direct teams
- •International sales span more than 25 countries
- •Many non-U.S. markets have historically used distributors
- •Direct operations are being expanded in selected European markets
Tandem’s strategy centers on expanding access to its insulin delivery systems through a broader reimbursement...
01
Broaden reimbursement accessshort-term
Coverage and benefit design directly affect patient adoption and recurring supply sales.
02
Expand the product platformmedium-term
New form factors and software features help differentiate the offering and support retention.
03
Increase international direct presencemedium-term
Direct operations can improve customer support, reimbursement control, and market execution.
04
Advance automation and closed-loop capabilitieslong-term
More automated insulin delivery can improve clinical outcomes and strengthen product relevance.
Tandem depends heavily on reimbursement access, distributor execution, and continued adoption of insulin pump therapy,...
Distributor dependence
A small number of independent distributors fulfill orders in key markets and may also sell competing products.
- Scope
- United States, Canada, and international markets
- Materiality
- high
Supplier concentration and manufacturing disruption
The company relies on third-party suppliers for components and products, creating supply continuity risk.
- Scope
- Components, consumables, and device manufacturing
- Materiality
- high
Competitive and technology obsolescence
Alternative pumps, CGM-linked systems, or new diabetes therapies could reduce the appeal of Tandem's devices.
- Scope
- Insulin delivery and automated insulin delivery market
- Materiality
- high
Regulatory and clinical execution risk
Clearances, trials, and human factors studies are required before commercialization of new products.
- Scope
- U.S. FDA and foreign regulators
- Materiality
- medium
Revenue recognition for pumps and supplies
Quarterly comparability and mix between hardware and consumables
Warranty reserve estimates
Cost of sales and accrued liabilities
Inventory and purchase commitments
Gross margin and inventory valuation
Acquisition-related intangible assets
Operating expenses and balance sheet carrying values
Debt and convertible note accounting
Interest expense, dilution, and liquidity presentation
: 29.4.2026